Kyverna Therapeutics, Inc.
Key Metrics
- Previous Close
- $4.70
- 52-Week Range
- $4.40 – $13.67
- Market Cap
- $283.23M
- P/E (TTM)
- —
- EPS (TTM)
- -2.75
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 2.10
- PEG Ratio
- —
- Return on Equity
- -110.69%
- Return on Assets
- -54.14%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 7.01
- Debt/Equity
- 0.24
- Total Debt
- $32.45M
- Free Cash Flow
- $-98.95M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $145.11M
Market Snapshot
About
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. The company's lead product candidate utilizes chimeric antigen receptor (CAR) T-cell technology to selectively deplete B cells that drive autoimmune conditions. Kyverna's pipeline targets diseases such as lupus nephritis, myasthenia gravis, and multiple sclerosis, applying oncology-derived cell therapy approaches to autoimmune disorders.